Hepatocellular Carcinoma
Conditions
Interventions
cTACE treatment group:cTACE
Microsphere TAE treatment group:Microsphere TAE
Sponsors
Zhongshan Hospital of Fudan University
Eligibility
Sex/Gender
Male
Inclusion criteria
Inclusion criteria: 1. Clinically or pathologically diagnosed as hepatocellular carcinoma; 2. Middle stage liver cancer that cannot be resected; 3. At least one measurable target lesion; 4. ECOG score 0-2 points; 5. Liver function status is Child-Pugh A or B7; 6. The expected life is at least 3 months; 7. Age>18 years old, = 85 years old, gender unlimited; 8. Peripheral blood WBC>3 X 10 * 9/L; 9. Platelet count = 75 X 10 * 9/L; 10. Total bilirubin concentration = 2 mg/dl; 11. Serum albumin = 28 g/L; 12. ALT and AST = 5 times the upper limit of normal value (ULN); 13. Serum creatinine = 1.5 times of ULN.
Exclusion criteria
Exclusion criteria: 1. Uncontrolled infection; 2. Cholangiocarcinoma or mixed cell carcinoma, combined with other tumors; 3. History of drug allergy; 4. HIV infection; 5. Pregnancy; 6. Within the first 30 days, severe bleeding symptoms or clear gastrointestinal bleeding tendency (stool occult blood++and above can not be included in the group); 7. Targeting and immunotherapy have been used before enrollment.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| ORR; | — |
Secondary
| Measure | Time frame |
|---|---|
| OS;PFS;TTP;AFP response;DCR;Safety; | — |
Countries
China
Contacts
Public ContactChen Rongxin
Zhongshan Hospital of Fudan University
Outcome results
None listed